Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $138,571.86 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 15,414 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $8.99 per share, for a total transaction of $138,571.86. Following the purchase, the director directly owned 16,638,150 shares of the company’s stock, valued at approximately $149,576,968.50. The trade was a 0.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Trading Down 1.2%

Shares of Artiva Biotherapeutics stock opened at $9.82 on Friday. The firm’s 50 day simple moving average is $9.13 and its two-hundred day simple moving average is $6.32. The firm has a market capitalization of $242.75 million, a price-to-earnings ratio of -2.77 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, sell-side analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. HC Wainwright raised their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, Wedbush upped their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ARTV. Bank of America Corp DE boosted its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $41,000. Dimensional Fund Advisors LP purchased a new position in shares of Artiva Biotherapeutics during the 1st quarter valued at about $131,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter valued at about $91,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Artiva Biotherapeutics during the 1st quarter valued at about $139,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.